An activation of the endocannabinoid system (ECS) in obesity with increased concentrations
of endocannabinoids in several tissues and in the circulation is described in this review. This …

Endoannabinoids regulate energy balance by modulating hypothalamic circuits controlling
food intake and energy expenditure. However, convincing evidence has accumulated …

The endocannabinoid system elicits multiple physiologic functions that are not fully
understood. Antagonism of cannabinoid type 1 (CB1) receptors has been the only …

Many different regulatory actions have been attributed to endocannabinoids, and their
involvement in several pathophysiological conditions is under intense scrutiny. Cannabinoid …

The endocannabinoid system (ECS), including cannabinoid type 1 and type 2 receptors
(CB1R and CB2R), endogenous ligands called endocannabinoids and their related …

Blockade of the CB1 receptor is one of the promising strategies for the treatment of obesity.
The first selective CB1 receptor antagonist, rimonabant, which has already successfully …

There is growing interest in the commercialisation of the CB1 receptor antagonist
Rimonabant in Europe for the treatment of obesity and the metabolic syndrome. Clinical …

During the last few years, the endocannabinoid system has emerged as a highly relevant
topic in the scientific community. Many different regulatory actions have been attributed to …

Two receptors have been cloned to date for the psychotropic compound Δ 9-
tetrahydrocannabinol, and termed cannabinoid CB 1 and CB 2 receptors. Their endogenous …

Obesity and cardiometabolic risk continue to be major public health concerns. A better
understanding of the physiopathological mechanisms leading to obesity may help to identify …